Literature DB >> 19713519

Antibiotics for emerging pathogens.

Michael A Fischbach1, Christopher T Walsh.   

Abstract

Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. New antibiotics are needed to combat these bacterial pathogens, but progress in developing them has been slow. Historically, most antibiotics have come from a small set of molecular scaffolds whose functional lifetimes have been extended by generations of synthetic tailoring. The emergence of multidrug resistance among the latest generation of pathogens suggests that the discovery of new scaffolds should be a priority. Promising approaches to scaffold discovery are emerging; they include mining underexplored microbial niches for natural products, designing screens that avoid rediscovering old scaffolds, and repurposing libraries of synthetic molecules for use as antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713519      PMCID: PMC2802854          DOI: 10.1126/science.1176667

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  46 in total

Review 1.  How many antibiotics are produced by the genus Streptomyces?

Authors:  M G Watve; R Tickoo; M M Jog; B D Bhole
Journal:  Arch Microbiol       Date:  2001-11       Impact factor: 2.552

Review 2.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

3.  Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants.

Authors:  C Freiberg; H P Fischer; N A Brunner
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 4.  From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis.

Authors:  Susan E Dorman; Richard E Chaisson
Journal:  Nat Med       Date:  2007-03       Impact factor: 53.440

Review 5.  The biosynthetic potential of myxobacteria and their impact in drug discovery.

Authors:  Silke C Wenzel; Rolf Müller
Journal:  Curr Opin Drug Discov Devel       Date:  2009-03

Review 6.  Genome mining for novel natural product discovery.

Authors:  Gregory L Challis
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

7.  Recognition of antimicrobial peptides by a bacterial sensor kinase.

Authors:  Martin W Bader; Sarah Sanowar; Margaret E Daley; Anna R Schneider; Uhnsoo Cho; Wenqing Xu; Rachel E Klevit; Hervé Le Moual; Samuel I Miller
Journal:  Cell       Date:  2005-08-12       Impact factor: 41.582

8.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Authors:  Jun Wang; Stephen M Soisson; Katherine Young; Wesley Shoop; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Gopalakrishnan Parthasarathy; Yui S Tang; Richard Cummings; Sookhee Ha; Karen Dorso; Mary Motyl; Hiranthi Jayasuriya; John Ondeyka; Kithsiri Herath; Chaowei Zhang; Lorraine Hernandez; John Allocco; Angela Basilio; José R Tormo; Olga Genilloud; Francisca Vicente; Fernando Pelaez; Lawrence Colwell; Sang Ho Lee; Bruce Michael; Thomas Felcetto; Charles Gill; Lynn L Silver; Jeffery D Hermes; Ken Bartizal; John Barrett; Dennis Schmatz; Joseph W Becker; Doris Cully; Sheo B Singh
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

9.  A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence.

Authors:  Chia-I Liu; George Y Liu; Yongcheng Song; Fenglin Yin; Mary E Hensler; Wen-Yih Jeng; Victor Nizet; Andrew H-J Wang; Eric Oldfield
Journal:  Science       Date:  2008-02-14       Impact factor: 47.728

10.  A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore.

Authors:  J Richard Miller; Steve Dunham; Igor Mochalkin; Craig Banotai; Matthew Bowman; Susan Buist; Bill Dunkle; Debra Hanna; H James Harwood; Michael D Huband; Alla Karnovsky; Michael Kuhn; Chris Limberakis; Jia Y Liu; Shawn Mehrens; W Thomas Mueller; Lakshmi Narasimhan; Adam Ogden; Jeff Ohren; J V N Vara Prasad; John A Shelly; Laura Skerlos; Mark Sulavik; V Hayden Thomas; Steve VanderRoest; LiAnn Wang; Zhigang Wang; Amy Whitton; Tong Zhu; C Kendall Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-22       Impact factor: 11.205

View more
  518 in total

1.  Exometabolome analysis identifies pyruvate dehydrogenase as a target for the antibiotic triphenylbismuthdichloride in multiresistant bacterial pathogens.

Authors:  Timo Birkenstock; Manuel Liebeke; Volker Winstel; Bernhard Krismer; Cordula Gekeler; Maria J Niemiec; Hans Bisswanger; Michael Lalk; Andreas Peschel
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 2.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

Review 3.  The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors.

Authors:  L Hedstrom; G Liechti; J B Goldberg; D R Gollapalli
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Evaluating the suitability of essential genes as targets for antibiotic screening assays using proteomics.

Authors:  Ashley Chessher
Journal:  Protein Cell       Date:  2012-01       Impact factor: 14.870

5.  The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance.

Authors:  Ján Burian; Santiago Ramón-García; Gaye Sweet; Anaximandro Gómez-Velasco; Yossef Av-Gay; Charles J Thompson
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

6.  Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.

Authors:  Jun-Ren Sun; Ming-Chin Chan; Tein-Yao Chang; Wei-Yao Wang; Tzong-Shi Chiueh
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

Review 7.  The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts.

Authors:  R Craig MacLean; Alex R Hall; Gabriel G Perron; Angus Buckling
Journal:  Nat Rev Genet       Date:  2010-06       Impact factor: 53.242

8.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

9.  Grand challenge commentary: Exploiting single-cell variation for new antibiotics.

Authors:  Erick Strauss
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

10.  Heterologous production of the lantibiotic Ala(0)actagardine in Escherichia coli.

Authors:  Yanxiang Shi; Alejandro Bueno; Wilfred A van der Donk
Journal:  Chem Commun (Camb)       Date:  2012-11-18       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.